Barclays
NAVB

Barclays’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Barclays’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-325
Closed -$7K – 6617
2015
Q4 		$7K Buy
325
+175
+117% +$6.08K ﹤0.01% 5506
2015
Q3 		$6K Sell
150
-125
-45% -$4.71K ﹤0.01% 6016
2015
Q2 		$6K Hold
275
– – ﹤0.01% 6394
2015
Q1 		$6K Buy
+275
New +$9.31K ﹤0.01% 6526
2014
Q4 		– Sell
-620
Closed -$12K – 7763
2014
Q3 		$12K Sell
620
-405
-40% -$10.7K ﹤0.01% 6799
2014
Q2 		$21K Buy
1,025
+555
+118% +$17.9K ﹤0.01% 6497
2014
Q1 		$9K Buy
470
+405
+623% +$15.4K ﹤0.01% 6990
2013
Q4 		$3K Sell
65
-3,050
-98% -$119K ﹤0.01% 7302
2013
Q3 		$125K Buy
3,115
+1,190
+62% +$69.4K ﹤0.01% 5445
2013
Q2 		$103K Buy
+1,925
New +$96.1K ﹤0.01% 5765

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's NAVB Position: Q2 2018 in Review

Barclays held its Navidea Biopharmaceuticals Inc. (NAVB) position steady in Q2 2018 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7509.

Barclays first reported a position in NAVB in Q2 2013 and has held it in 19 quarters since. The position peaked at $234K in Q2 2016. 54 funds tracked by Wall St. Rank hold NAVB as of Q2 2018.

  • Barclays held 0 shares of Navidea Biopharmaceuticals Inc. worth $0 as of Q2 2018.
  • Barclays left its Navidea Biopharmaceuticals Inc. share count unchanged in Q2 2018.
  • Navidea Biopharmaceuticals Inc. made up ﹤0.01% of Barclays's portfolio in Q2 2018, its #7509 holding.
  • Barclays first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and has held it in 19 quarters since.
  • Barclays's Navidea Biopharmaceuticals Inc. position peaked at $234K in Q2 2016.
  • 54 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2018.

Based on Barclays's 13F filing for Q2 2018, filed 14 Aug 2018.